Why the study?
Specific recommendations for height exponents to normalize LV mass are lacking due to a scarcity of normal cohorts to define them.
Does indexing left ventricular mass to sex-specific height exponents improve prognostic prediction of adverse cardiovascular events compared to body surface area indexing in Asian subjects with hypertension?
Does indexing left ventricular mass to sex-specific height exponents improve prognostic prediction of adverse cardiovascular events compared to body surface area indexing in Asian subjects with hypertension?
Using sex-specific height exponents for indexing left ventricular mass increases the diagnosis of LVH but does not significantly improve the prediction of adverse cardiovascular events compared to body surface area indexing.
Answers are grounded in this paper and cite their sources.
Height-based indexing detects more LVH without improving event prediction; leaves open optimal method in Asian hypertension.
BACKGROUND: Left ventricular hypertrophy (LVH) is a strong predictor of adverse outcomes. Although normalizing LV mass (LVM) to height exponents reduced variability from body size, specific recommendations for height exponents are lacking due to a scarcity of normal cohorts to define appropriate height exponents. OBJECTIVES: The authors aimed to show the diagnostic and prognostic implications of establishing height exponents specific to sex, ethnicity, and imaging modality. METHODS: Nonoverweight/nonobese Asian healthy volunteers (n = 416) were used to establish appropriate height exponents. The impact of these height exponents was examined in a separate cohort of Asian subjects with hypertension (n = 878). All individuals underwent standardized cardiovascular magnetic resonance imaging. The primary outcome was a composite of acute coronary syndrome, heart failure hospitalization, stroke, and cardiovascular mortality. RESULTS: The height exponents for healthy female subjects and male subjects were 1.57 and 2.33, respectively. LVH was present in 27% of individuals with hypertension when indexed to body surface area and 47% when indexed to sex-specific height exponents. Most individuals reclassified to LVH with height exponents were overweight or obese. There were 37 adverse events over 60 months (37-73 months) of follow-up. Regardless of indexing method, LVH was independently associated with increased adverse events (height exponent HR: 2.80 [95% CI: 1.25-6.29; P = 0.013]; body surface area HR: 5.43 [95% CI: 2.49-11.8; P < 0.001]). CONCLUSIONS: Reference ranges specific to ethnicity, sex, and imaging modality are necessary to establish appropriate height exponents. Although using height exponents resulted in more LVH reclassification, this did not translate to a notable improvement in event prediction.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: